908 Devices (MASS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
3 Mar, 2026Executive summary
Achieved $17.4 million in Q4 2025 revenue from continuing operations, up 21% year-over-year, and $56.2 million for the full year, up 18% year-over-year.
Positive Adjusted EBITDA of $0.7 million in Q4 2025, a turnaround from a $4 million loss in the prior year period, with full-year Adjusted EBITDA loss reduced to $9.6 million.
Recurring revenue grew 22% in 2025 to $19.5 million, now comprising 35% of total revenue.
Installed base expanded to 3,736 devices by year-end 2025, up from 2,422 in 2023.
Ended 2025 with $113 million in cash and no debt.
Financial highlights
Q4 gross profit was $9.2 million (53% margin), with Adjusted gross margin for Q4 at 57%, up 530 basis points year-over-year.
Full-year 2025 gross profit reached $28.4 million, with Adjusted gross profit at $31.9 million and Adjusted gross margin at 57%.
Net income from continuing operations in Q4 was $4.4 million, compared to a $16 million loss in the prior year; full-year net loss narrowed to $33.3 million from $53.1 million.
Full year recurring revenue grew 22% to $19.5 million, representing 35% of total revenue.
Operating expenses remained stable at $54.1 million in 2025.
Outlook and guidance
2026 revenue expected between $64.5 million and $67.5 million, 15%-20% growth over 2025.
Adjusted gross margins targeted in the mid-to-high 50% range, with at least 100 basis points expansion.
Adjusted EBITDA loss expected to be cut in half in 2026, reaching low to mid single-digit millions.
Long-term goal to reach $100 million+ in annual revenue.
Latest events from 908 Devices
- Transformation and innovation in handheld detection devices drive strong growth and profitability.MASS
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Strong growth, innovation, and global expansion set the stage for profitability by 2027.MASS
Leerink Global Healthcare Conference 20269 Mar 2026 - Up to $100 million in securities to fund growth in handheld chemical analysis markets.MASS
Registration Filing9 Mar 2026 - Handheld detection tools, new products, and software drive growth and recurring revenue in 2026.MASS
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Q2 revenue up 16% to $14M; 2024 outlook reaffirmed at $63–$65M, with strong handheld growth.MASS
Q2 20242 Feb 2026 - Handheld growth, RedWave integration, and innovation set the stage for future acceleration.MASS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - RedWave acquisition and product innovation drive growth, margin gains, and market expansion.MASS
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Q3 revenue up 17%, but net loss widened on goodwill impairment and RedWave acquisition costs.MASS
Q3 202415 Jan 2026 - Portfolio expansion, RedWave synergies, and operational changes position for growth in 2025.MASS
Stifel 2024 Healthcare Conference13 Jan 2026